Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Fina

- Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Highe...

Related Keywords

United States , Texas , Boston , Massachusetts , North Carolina , American , Conor Richardson , Mirvetuximab Soravtansine , Taylor Schreiber , American Society Of Hematology , Exchange Commission , Shattuck Labs Inc , Nasdaq , Cancer Research , Ono Pharmaceutical Co Ltd , Health Care Conference Boston , Development Rd Expenses , Rna Work In Cancer Research , Higher Risk Myelodysplastic Syndromes , Acute Myeloid Leukemia , American Society , Annual Meeting , Chief Executive Officer , Cancer Cell , Milestones Expected , Stage Pipeline , Initial Enrollment , Ongoing Phase , Clinical Trial , Presented Positive Interim Data , Acquired Resistance , Annual Health Care Conference , Global Biopharma Conference , Biotechc Suite Fireside Chat Series , Cancer Research Annual Meeting , San Diego , Ono Enter , Collaboration Agreement , Closes Financing , Cash Equivalents , Shattuck Labs , Agonist Redirected Checkpoint , Annual Report , Safe Harbor , Private Securities Litigation Reform Act , Media Contact , Ended December , Diluted Per Common Share Data ,